C86.50
Angioimmunoblastic T-cell lymphoma not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) NOS
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) not having achieved remission
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) with failed remission
- Angioimmunoblastic T-cell lymphoma NOS
- Angioimmunoblastic T-cell lymphoma with failed remission
Medical Intelligence & Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive type of non-Hodgkin lymphoma that affects the lymphatic system. This condition involves the abnormal growth of T-cells, a type of white blood cell important for immune defense. When AITL is diagnosed as not having achieved remission, it indicates that the disease persists despite treatment. Understanding this condition can help patients and their loved ones better grasp what the diagnosis entails and the importance of ongoing management.
Causes & Symptoms
Clinical Causes: The exact cause of AITL is unknown, but it is believed to result from genetic mutations within T-cells that lead to uncontrolled growth. Certain immune system abnormalities may contribute to the development of this lymphoma. There is no clear evidence linking lifestyle factors like smoking or diet directly to this disease. Some cases have been associated with viral infections, such as Epstein-Barr virus (EBV), though this is not always the case.
Key Symptoms: Swollen lymph nodes in the neck, chest, armpits, or groin Unexplained fever that persists over time Night sweats, often severe and disruptive Unintentional weight loss Itching skin (pruritus) Fatigue or general weakness Abdominal discomfort or swelling due to enlarged lymph nodes or organs Rashes or skin lesions in some cases Difficulty breathing if lymph nodes in the chest are enlarged Possible signs of immune system dysfunction, such as frequent infections
Diagnostic & Treatment
Diagnosis Path: The diagnosis of AITL involves a combination of clinical evaluation, blood tests, imaging studies, and biopsy procedures. Key steps include: - Medical history review and physical examination - Blood tests to evaluate blood cell counts and immune function - Imaging scans such as CT or PET to identify affected areas - Lymph node biopsy, where a sample of tissue is examined microscopically for characteristic cancer cells - Additional tests like immunohistochemistry and molecular studies to confirm the subtype of lymphoma and assess disease activity
Treatment Protocols: Managing AITL not in remission typically requires comprehensive treatment strategies. Options may include: - Chemotherapy regimens aimed at destroying cancer cells - Targeted therapies that focus on specific molecules involved in tumor growth - Immunotherapy approaches to boost the immune system's ability to fight the disease - Stem cell or bone marrow transplants in suitable candidates, offering the possibility of a cure in some cases - Supportive care to manage symptoms and improve quality of life It is important to work closely with healthcare professionals to determine the most appropriate approach based on individual health status and disease progression.
Clinical Advice & FAQs
Billing Guidance
Is C86.50 a billable ICD-10 code?
Yes, C86.50 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.50?
Clinical documentation must specify the nature of Angioimmunoblastic T-cell lymphoma not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference